US2016143952A1PendingUtilityA1
Adipose-derived regenerative cells for treating liver injury
Est. expiryDec 7, 2021(expired)· nominal 20-yr term from priority
A61P 3/06A61P 37/06A61P 9/00A61P 3/10A61P 9/10A61P 43/00A61P 3/00A61P 27/02A61P 25/00A61P 17/02A61P 19/00A61K 35/28C12N 5/0667A61K 35/35A61K 9/0019A61P 19/10A61P 17/00C12N 2506/1384C12N 5/069A61P 1/16C12M 47/04A61P 19/04A61B 10/0283A61P 19/02A61P 1/04A61P 11/00A61M 2202/08A61P 21/00A61P 19/08A61P 1/00A61P 13/12A61M 1/0039A61K 48/00A61K 35/36A61K 35/32A61M 1/76
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating a patient comprising:
(a) providing a tissue removal system; (b) removing adipose tissue from a patient using the tissue removal system; (c) processing at least a part of the adipose tissue to obtain a concentration of stem cells other than the concentration of stem cells of the adipose tissue before processing; and (d) administering the stem cells to a patient without removing the stem cells from the tissue removal system before being administered to the patient.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.